WO2003049727A1 - Treatment of neoplasia - Google Patents

Treatment of neoplasia Download PDF

Info

Publication number
WO2003049727A1
WO2003049727A1 PCT/US2002/039310 US0239310W WO03049727A1 WO 2003049727 A1 WO2003049727 A1 WO 2003049727A1 US 0239310 W US0239310 W US 0239310W WO 03049727 A1 WO03049727 A1 WO 03049727A1
Authority
WO
WIPO (PCT)
Prior art keywords
thc
apoptosis
cells
receptors
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/039310
Other languages
English (en)
French (fr)
Inventor
Mitzi Nagarkatti
Prakash Nagarkatti
Robert Mckallip
Catherine Lombard
Seongho Ryu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virginia Commonwealth University
Original Assignee
Virginia Commonwealth University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Commonwealth University filed Critical Virginia Commonwealth University
Priority to EP02804754A priority Critical patent/EP1461027A4/en
Priority to AU2002357114A priority patent/AU2002357114B2/en
Priority to CA002468794A priority patent/CA2468794A1/en
Priority to JP2003550776A priority patent/JP2005516004A/ja
Priority to US10/497,911 priority patent/US20040259936A1/en
Publication of WO2003049727A1 publication Critical patent/WO2003049727A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Definitions

  • the abnormality is a malignancy of the immune system. autoimmune disease, septic shock, transplantation reaction and allergy. Most preferably the abnormality is leukemia or lymphoma, particularly primary acute lymphoblastic leukemia (ALL).
  • ALL primary acute lymphoblastic leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/US2002/039310 2001-12-07 2002-12-09 Treatment of neoplasia Ceased WO2003049727A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP02804754A EP1461027A4 (en) 2001-12-07 2002-12-09 TREATMENT OF NEOPLASIA
AU2002357114A AU2002357114B2 (en) 2001-12-07 2002-12-09 Treatment of neoplasia
CA002468794A CA2468794A1 (en) 2001-12-07 2002-12-09 Treatment of neoplasia
JP2003550776A JP2005516004A (ja) 2001-12-07 2002-12-09 新形成の治療
US10/497,911 US20040259936A1 (en) 2001-12-07 2002-12-09 Treatment of neoplasia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33673201P 2001-12-07 2001-12-07
US60/336,732 2001-12-07

Publications (1)

Publication Number Publication Date
WO2003049727A1 true WO2003049727A1 (en) 2003-06-19

Family

ID=23317407

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/039310 Ceased WO2003049727A1 (en) 2001-12-07 2002-12-09 Treatment of neoplasia

Country Status (6)

Country Link
US (1) US20040259936A1 (enExample)
EP (1) EP1461027A4 (enExample)
JP (1) JP2005516004A (enExample)
AU (1) AU2002357114B2 (enExample)
CA (1) CA2468794A1 (enExample)
WO (1) WO2003049727A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023232A3 (en) * 2003-09-04 2005-06-23 Affibody Ab Therapeutic, screening and diagnostic methods based on the effect of cb1 receptor modulation on lymphoproliferative disorders.
EP1736775A4 (en) * 2004-04-12 2008-03-12 Takeda Pharmaceutical NEW LIGAND OF A G-PROTEIN-COUPLED RECEPTOR PROTEIN AND USE THEREOF
US8178681B2 (en) 2004-10-28 2012-05-15 Shionogi & Co., Ltd. 3-carbamoyl-2-pyridone derivatives
CN115282279A (zh) * 2022-08-08 2022-11-04 暨南大学附属第一医院（广州华侨医院） CNR2通过介导DCs成熟及功能作为脓毒症急性肺损伤治疗靶点的应用
EP3968974A4 (en) * 2019-05-16 2023-01-11 Technion Research & Development Foundation Limited CANNABINOIDS AND THEIR USES

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632955B2 (en) * 2001-12-13 2009-12-15 National Health Research Institutes Indole compounds
US7528165B2 (en) * 2001-12-13 2009-05-05 National Health Research Institutes Indole compounds
US7456289B2 (en) * 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
MX2009005071A (es) * 2006-11-13 2009-05-25 Novartis Ag Compuestos de pirazol y triazol sustituidos como inhibidores de ksp.
EP2470508A1 (en) 2009-08-28 2012-07-04 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
CA2789151A1 (en) 2010-02-08 2011-08-11 Allergan, Inc. Pyridazine derivatives useful as cannabinoid-2 agonists
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
MX392150B (es) 2011-02-25 2025-03-21 Arena Pharm Inc Moduladores de receptores canabinoides.
JP5945554B2 (ja) 2011-02-25 2016-07-05 アリーナ ファーマシューティカルズ， インコーポレイテッド 縮合型アザ環の結晶形およびその調製プロセス（カンナビノイド受容体モジュレーター）
WO2016085941A1 (en) 2014-11-25 2016-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of cannabinoid receptor modulators

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990170A (en) * 1994-12-14 1999-11-23 Lifegroup S.P.A. Therapeutic use of mono and bicarboxylic acid amides active at the peripheral cannabinoid receptor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2735774B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
CA2340444A1 (en) * 1998-05-04 1999-11-11 The University Of Connecticut Cannabinoids selective for the cb2 receptor
CA2387892A1 (en) * 1999-10-18 2001-04-26 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
FR2800372B1 (fr) * 1999-11-03 2001-12-07 Sanofi Synthelabo Derives tricycliques d'acide 1-benzylpyrazole-3- carboxylique, leur preparation, les medicaments en contenant
JP2004502642A (ja) * 2000-02-11 2004-01-29 ブリストル−マイヤーズ　スクイブ　カンパニー カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990170A (en) * 1994-12-14 1999-11-23 Lifegroup S.P.A. Therapeutic use of mono and bicarboxylic acid amides active at the peripheral cannabinoid receptor

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] DEPARTMENT OF PHARMACOLOGY/TOXYCOLOGY (RICHMOND, USA); PETTIT ET AL.: "Immunohistochemical localization of the neural cannabinoid receptor in rat brain", XP002966527, accession no. STN Database accession no. 1998:91780 *
DATABASE CAPLUS [online] HEBREW UNIVERSITY, MEDICAL FACULTY (JERUSALEM, 91120, ISRAEL); MECHOULAM ET AL.: "Endogenous cannabinoid ligands-chemical and biological studies", XP002966526, accession no. STN Database accession no. 1996:595454 *
JOURNAL OF LIPID MEDIATORS AND CELL SIGNALLING, vol. 14, no. 1-3, 1996, pages 45 - 49 *
JOURNAL OF NEUROSCIENCE RESEARCH, vol. 51, no. 3, 1998, pages 391 - 402 *
See also references of EP1461027A4 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023232A3 (en) * 2003-09-04 2005-06-23 Affibody Ab Therapeutic, screening and diagnostic methods based on the effect of cb1 receptor modulation on lymphoproliferative disorders.
EP1736775A4 (en) * 2004-04-12 2008-03-12 Takeda Pharmaceutical NEW LIGAND OF A G-PROTEIN-COUPLED RECEPTOR PROTEIN AND USE THEREOF
US7927821B2 (en) 2004-04-12 2011-04-19 Takeda Pharmaceutical Company Limited Methods of screening for compounds which bind G protein-coupled receptors
US8178681B2 (en) 2004-10-28 2012-05-15 Shionogi & Co., Ltd. 3-carbamoyl-2-pyridone derivatives
US8367666B2 (en) 2004-10-28 2013-02-05 Shionogi & Co., Ltd. 3-carbamoyl-2-pyridone derivatives
EP3968974A4 (en) * 2019-05-16 2023-01-11 Technion Research & Development Foundation Limited CANNABINOIDS AND THEIR USES
US12274678B2 (en) 2019-05-16 2025-04-15 Technion Research & Development Foundation Limited Cannabinoids and uses thereof
CN115282279A (zh) * 2022-08-08 2022-11-04 暨南大学附属第一医院（广州华侨医院） CNR2通过介导DCs成熟及功能作为脓毒症急性肺损伤治疗靶点的应用
CN115282279B (zh) * 2022-08-08 2024-03-12 暨南大学附属第一医院（广州华侨医院） CNR2通过介导DCs成熟及功能作为脓毒症急性肺损伤治疗靶点的应用

Also Published As

Publication number Publication date
EP1461027A1 (en) 2004-09-29
AU2002357114B2 (en) 2008-07-24
US20040259936A1 (en) 2004-12-23
AU2002357114A1 (en) 2003-06-23
CA2468794A1 (en) 2003-06-19
EP1461027A4 (en) 2005-09-07
JP2005516004A (ja) 2005-06-02

Similar Documents

Publication Publication Date Title
McKallip et al. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease
US20040259936A1 (en) Treatment of neoplasia
Marcu et al. Cannabidiol enhances the inhibitory effects of Δ9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival
Lombard et al. CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: potential role for CB2-selective ligands as immunosuppressive agents
Kim et al. Lycopene suppresses the lipopolysaccharide‐induced phenotypic and functional maturation of murine dendritic cells through inhibition of mitogen‐activated protein kinases and nuclear factor‐κB
McKallip et al. Δ9-Tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo
ES2732005T3 (es) Una combinación de tetrahidrocannabinol y cannabidiol para uso para aumentar la radiosensibilidad en el tratamiento de un tumor cerebral
US20100029739A1 (en) Use of a combination of hypothermia inducing drugs
US20130022609A1 (en) Method of treating androgen independent prostate cancer
Pertwee Pharmacology of cannabinoid receptor ligands
US20090318526A1 (en) Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia
AU2009254936A1 (en) Anti-tumoural effects of cannabinoid combinations
WO2008040360A2 (en) Use of hypothermia inducing drugs to treat ischemia
US20180353461A1 (en) Use of cannabinoids as ceramide-generating anticancer agents in tumors of the hematopoietic and lymphoid tissues
KR20010072957A (ko) Ｈ2 수용체 작용제 및 기타 ｔ-세포 활성화제를 사용한ｔ-세포(ｃｄ4+ 및 ｃｄ8+) 활성화 및 보호 방법
WO2009124552A2 (en) Use of a combination of hypothermia inducing drugs
WO2010047663A1 (en) Use of tocotrienol composition for the prevention of cancer
ITMI971789A1 (it) Farmaco attivo nel ridurre la produzione di proteina mcp-1
ES2788744T3 (es) Cannabidiol para la prevención y el tratamiento de la enfermedad de injerto contra huésped
CN107375258B (zh) 一种抗肿瘤联合用药物及其在制备抗癌药物中的用途
WO2009071094A2 (en) Combination treatment of ischemic effects
NZ532844A (en) Use of a cannabinoid receptor agonist for the treatment of gastroesophageal reflux disease
Alexandrakis et al. The isoflavone genistein inhibits proliferation and increases histamine content in human leukemic mast cells
CN101489548A (zh) 大麻素受体激动剂作为诱导低体温药物在治疗局部缺血上的应用
Ogino et al. Indomethacin acts as an antitumor and anticachexic agent in colon 26-bearing CDF1 mice

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002357114

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2468794

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003550776

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002804754

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10497911

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2002804754

Country of ref document: EP